← Back to news
Clinical trialRSSFriday, April 24, 2026 · Yesterday

Single infusion of Roctavian linked to fewer bleeds in hemophilia A

WHY IT MATTERS

If you have severe hemophilia A, Roctavian could mean switching from frequent infusions or injections to a single treatment that protects you from bleeds for years.

A new treatment called Roctavian was given as a single injection to men with severe hemophilia A (a bleeding disorder). Seven years later, most patients had fewer bleeding episodes and needed less preventive medicine. This suggests the treatment's benefits can last for many years.

Roctavian (valoctocogene roxaparvovec-rvox) was associated with fewer bleeding episodes and less need for preventive treatment, or prophylaxis, in most adult men with severe hemophilia A for up to seven years after a single infusion, according to final results from a completed clinical trial. The Phase 1/2 clinical trial (NCT02576795) tested the safety and efficacy of […] The post Single infusion of Roctavian linked to fewer bleeds in hemophilia A appeared first on Hemophilia News Today .

ASK YOUR DOCTOR

Ask your hematologist if you're a candidate for Roctavian and whether long-term follow-up data like this changes treatment options for your situation.

Find a specialist →Learn more ↗
gene therapyhemophiliableeding disorderlong-term outcomesclinical trial

Related conditions

Hemophilia A